- EG-Mirotin is a RGD-motif containing human recombinant polypeptide (compound name:
EGT022 / 58 amino acids / MW: 6.1-kDa).
- First in Class novel subcutaneous drug targeted to suppress edema and vascular leakage in
abnormal retinal microvasculature through that normalization and stabilization of damaged retinal
- Pre-clinical toxicity studies were successfully completed both in-house and in Europe
(Switzerland) with no signs of toxicity and/or genotoxicity. Additional studies confirmed there were
no undesirable angiogenesis and effects on tumor growth. Pre-clinical efficacy studies were
conducted in both the Oxygen-Induced Retinopathy model and Streptozotocin-induced diabetic
rat model. Retinal flat mount and angiography results have demonstrated formation of stabilized
and mature retinal vasculature, and Optical Coherence Tomography (OCT) measurements have
shown a statistically significant reduction in macular edema.
- Phase I safety studies conducted in Europe (Netherlands) was successful. Treatment with EGMirotin
in single and multiple doses was well tolerated in all subjects (both healthy and diabetic
- Phase IIa proof-of-concept studies are currently being conducted in Europe (France).
- Laser Photocoagulation has been widely used to treat eye diseases, but only covers Proliferative
Diabetic Retinopathy and Age-related Macular Degeneration. Drugs such as anti-VEGF and
steroids are available, but vary in efficacy/side effects, and are usually for late-stage Diabetic
- First in Class novel subcutaneous therapeutic for Non-proliferative Diabetic Retinopathy that is
competitive in terms of both route of administration and cost versus current alternate treatments.
- Novel sub-cutaneous therapeutic for Diabetic Retinopathy (Non-proliferative Diabetic Retinopathy / NPDR)
- Targeted to suppress edema and vascular leakage in abnormal capillaries in NPDR patients